Differentiation of porphyria cutanea tarda symptomatica from other types of porphyria by measurement of isocoproporphyrin in faeces

G. H. ELDER

From the Department of Medical Biochemistry, Welsh National School of Medicine, Heath Park, Cardiff CF4 4XN

SYNOPSIS The faecal porphyrin patterns of 24 patients with porphyria cutanea tarda symptomatica (PCTS), eight patients with variegate porphyria, three patients with other types of porphyria, and 20 non-porphyric subjects have been compared using a two-dimensional thin layer chromatographic technique that separates porphyrins of the isocoproporphyrin series from other faecal porphyrins. The 'isocoproporphyrin':coproporphyrin ratio ranged from 0.1 to 5.6 for patients with PCTS, whereas in other types of porphyria and non-porphyric subjects it was 0.05 or less.

Porphyria cutanea tarda symptomatica (PCTS) is a syndrome characterized by skin lesions, overproduction of porphyrins with four to eight carboxylic acid side chains, and the absence of the acute attacks of porphyria, often induced by drugs, which are an important feature of the other hepatic porphyrias (Taddeini and Watson, 1968; Dowdle et al, 1970). It is the commonest type of cutaneous hepatic porphyria in the United Kingdom and is seen most frequently in middle-aged men with alcoholic liver disease, although it also occurs in association with other types of liver disease and in patients taking oestrogens. PCTS in more than one member of a family is rare (Dehlin et al, 1973). Hepatic siderosis is frequent and the condition is particularly common where iron overload and alcoholism occur together, as among the Bantu in South Africa. Depletion of body iron stores by repeated venesection leads to remission in the majority of patients (Ramsay et al, 1974).

The main problem in the diagnosis of PCTS is differentiation from variegate porphyria (VP). Since the skin lesions in both conditions are identical, and may be the sole clinical manifestation, the distinction depends on differences in the patterns of excretion of haem precursors (Eales et al, 1963). Recently, it has been shown that the faeces of patients with PCTS contain a previously unrecognized group of tetracarboxylic porphyrins— isocoproporphyrin, de-ethylisocoproporphyrin, dehydroisocoproporphyrin, and hydroxyisocoproporphyrin (Elder, 1971a, 1972). The probable origin and metabolism of these porphyrins has been described (Elder, 1974). This paper assesses their diagnostic significance.

Patients and Methods

Patients

Patients with porphyria were classified according to current clinical and biochemical criteria (Elder et al, 1972). Table I shows the results of measurements of haem precursors in urine and faeces for the patients with hepatic porphyria. Twenty-four patients with PCTS were studied, 19 Europeans and five Bantu. Six of the former were in remission when investigated. Of the European patients, 10 had liver damage due to alcohol, two had cryptogenic cirrhosis, one had infective hepatitis, four developed PCTS while on oral contraceptives, and in two patients no aetiological agent was implicated. The eight patients with variegate porphyria came from six apparently unrelated European families. Clinical details of the patients with erythropoietic protoporphyria and congenital erythropoietic porphyria have been published (Nicholson et al, 1973).

Twenty subjects without clinical or biochemical evidence of porphyria were also studied. Of these, eight were normal, six were in hospital for minor surgery, three had alcoholic cirrhosis, and three had cryptogenic cirrhosis. Two of the patients with liver disease had hyperbilirubinaemia (serum bilirubin 46 and 102 μmol/l).
Porphyrins
Porphyrins for use as standards were isolated as their methyl ester derivatives from porphyric urine or faeces, as described by Elder (1972).

Extraction of Porphyrins from Faeces
Porphyrins were extracted from faeces (0·5-1·0 g wet weight) with ether acetic acid, as described by Rimington (1971). The total volume of the ether-acetic acid extract was measured, and an aliquot (0·2-0·4 vol) was taken for estimation of the coproporphyrin and protoporphyrin fractions (Rimington, 1971). The porphyrins in the rest of the extract were transferred to 1·4 m-HCl by shaking with successive volumes (2·5 ml) of acid until no more porphyrin was extracted. The pH of the acid extract was adjusted to pH 3·5 with saturated aqueous sodium acetate, and t alc (acid-washed) was added in batches until all porphyrin was absorbed. The talc was removed by filtration, washed with water, and partially dried by suction. Porphyrins were eluted from the moist t alc with methanol-H2SO4 (19:1, v/v) and the eluate was kept in the dark at room temperature for 20 hours to allow complete esterification. The porphyrin methyl esters were transferred to chloroform (Falk, 1964), which was washed once with 2M-NH4OH and three times with water, dried by filtration through chloroform-moistened paper, and removed by distillation at 40-50°C under reduced pressure.

Measurement of Porphyrin Ratios
Porphyrin methyl esters were fractionated by two-dimensional thin-layer chromatography on silica gel plates (Camag D5 or Merck silica gel 60) (Elder, 1971b). In this system the methyl esters of three members of the isocoproporphyrin series—hydroisocoproporphyrin, de-ethylisocoproporphyrin, and de-hydroisocoproporphyrin—migrate together as a single spot between coproporphyrin and 'pentacarboxylic porphyrin methyl esters (fig 1). Porphyrins migrating in this position and identified by co-chromatography with authentic isocoproporphyrin methyl ester, but not identified further, are subsequently referred to as 'isocoproporphyrin'.

Coproporphyrin, 'isocoproporphyrin', and hydroxyisocoproporphyrin were recovered from the silica gel by elution with chloroform-methanol (4:1, v/v). The eluates were made up to the same volume, usually 3·0 or 4·0 ml, and the concentration of porphyrin in each was determined by spectrophotometry using the millimolar extinction coefficient for coproporphyrin tetramethyl ester in chloroform given by Falk (1964). 

Screening Test for 'Isocoproporphyrin' in Faeces
About 0·5 g wet faeces was suspended in 4·0 ml methanol-H2SO4 (9:1, v/v) for 48 hours in the dark at room temperature. After centrifugation, the supernatant was removed, and mixed with 2·0 ml chloroform, and the esters were recovered as described above. An aliquot of this extract containing sufficient porphyrin, as judged by the intensity of red fluorescence in ultraviolet light, was applied as a 2 cm streak to a 200 x 200 x 0·25 mm silica gel 60 plate (Merck), fractionated by one-dimensional thin-layer chromatography in chloroform-kerosene-methanol (200:100:6, by vol) (Elder, 1971b), and

Table 1 Haem precursors in urine and faeces

<table>
<thead>
<tr>
<th>No. of Patients</th>
<th>PBG (μmol/24h)</th>
<th>Copro (nmol/24h)</th>
<th>Uro (μmol/24h)</th>
<th>PBG (μmol/g dry wt)</th>
<th>Copro (nmol/g dry wt)</th>
<th>Proto</th>
<th>Proto Copro ratio</th>
<th>Etherinsol (μmol/g dry wt)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCTS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Active</td>
<td>13</td>
<td>527 (12)</td>
<td>4848</td>
<td>188</td>
<td>174</td>
<td>0·97</td>
<td>219 (12)</td>
<td></td>
</tr>
<tr>
<td>Remission</td>
<td>6</td>
<td>223·947</td>
<td>2031·12 274</td>
<td>108·395</td>
<td>55·468</td>
<td>0·36-2·06</td>
<td>36·430</td>
<td></td>
</tr>
<tr>
<td>Bantu</td>
<td>5</td>
<td>316</td>
<td>88·656</td>
<td>108</td>
<td>171</td>
<td>1·60</td>
<td>100 (5)</td>
<td></td>
</tr>
<tr>
<td>Variegate</td>
<td>8</td>
<td>736</td>
<td>3213</td>
<td>38·223</td>
<td>30·498</td>
<td>0·51-3·50</td>
<td>13·166</td>
<td></td>
</tr>
<tr>
<td>Acute intermittent</td>
<td>1</td>
<td>64·150</td>
<td>709·749</td>
<td>87</td>
<td>57</td>
<td>7·40</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal range</td>
<td>&lt;9</td>
<td>&lt;244</td>
<td>&lt;36</td>
<td>&lt;41</td>
<td>&lt;135</td>
<td>0·28</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Differentiation of *porphyria cutanea tarda symptomatica* from other types of *porphyria*

**Fig 1** Two-dimensional thin-layer chromatography of porphyrin esters from the faeces of a patient with PCTS photographed under ultraviolet light: 1 = protoporphyrin; 2 = coproporphyrin; 3 = 'isocoproprphyrin'; 4, 5, 6 = penta-, hexa-, and hepta-carboxylic porphyrins; 7 = hydroxyisocoproprphyrin; 8 = origin.

inspected under ultraviolet light for the presence of a porphyrin migrating between coproporphyrin and pentacarboxylic porphyrin esters. The identity of any porphyrin detected in this position was confirmed by two-dimensional thin-layer chromatography.

**OTHER METHODS**

Faecal ether-insoluble porphyrins ('X-porphyrin' fraction) were measured as described by Rimington *et al* (1968). Urinary porphobilinogen, coproporphyrin, and uroporphyrin fractions were determined by the methods of Mauzerall and Granick (1956) and Rimington (1971). Urine porphyrins were isolated as their methyl esters (Dowdle *et al*, 1970), fractionated, and estimated as described above.

**Results**

Porphyrins of the isocoproprphyrin series were identified in the faeces of all patients with PCTS and of three of the eight patients with VP. Hydroxy-isocoproprphyrin was always present in smaller amounts than 'isocoproprphyrin'. The screening test using one-dimensional thin-layer chromatography was as effective as the two-dimensional thin-layer chromatography technique for the detection of 'isocoproprphyrin'. A typical chromatogram illustrating the difference between the faecal porphyrin excretion patterns of PCTS and VP is shown (fig 2).

Porphyrins of the isocoproprphyrin series were present in the urine from four of the six patients with PCTS in which the urine porphyrins were fractionated by thin-layer chromatography (table II). The figures for porphyrin excretion in these patients indicate that in PCTS isocoproprphyrin and related porphyrins are predominantly excreted in the faeces, as reported previously (Elder, 1971a, 1974).

Trace amounts of a porphyrin migrating between coproporphyrin and pentacarboxylic porphyrin esters, and therefore tentatively identified as belonging to the isocoproprphyrin series, were detected in the faeces of four of the 20 non-porphyric
subjects, one of these being a patient with cirrhosis. Hydroxyisocoproporphyrin was not detected in the faeces from any of the non-porphyric subjects.

Figure 3 shows that the 'isocoproporphyrin': coproporphyrin ratio is higher in PCTS than in other types of porphyria and that measurement of this ratio is an effective way of differentiating PCTS and VP. Thus, with the exception of two of the patients investigated during remission, there is at least a 10-fold difference in the ratio between the two conditions. In PCTS there was no correlation between the ratio and the level of any faecal porphyrin fraction.

In PCTS the excretion of uroporphyrin decreases progressively during remission. The 'isocoproporphyrin':coproporphyrin ratio is also lower during remission (fig 3) and there is a statistically significant correlation between the ratio and urinary uropor-

---

**Table II** Excretion of isocoproporphyrin series in urine and faeces

<table>
<thead>
<tr>
<th>Patient</th>
<th>Urine (nmol/24h)</th>
<th>Faeces (nmol/24h)</th>
<th>'Isocoprop':Copro Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>Isocopro Series</td>
<td>Copro Fraction</td>
<td>Isocopro: Copro Ratio</td>
</tr>
<tr>
<td>6</td>
<td>12 805</td>
<td>17</td>
<td>3450</td>
</tr>
<tr>
<td>7</td>
<td>6928</td>
<td>0</td>
<td>2687</td>
</tr>
<tr>
<td>8</td>
<td>2006</td>
<td>5</td>
<td>7908</td>
</tr>
<tr>
<td>9</td>
<td>2825</td>
<td>0</td>
<td>2168</td>
</tr>
<tr>
<td>10</td>
<td>5292</td>
<td>652</td>
<td>2687</td>
</tr>
<tr>
<td>11</td>
<td>6723</td>
<td>67</td>
<td>3664</td>
</tr>
</tbody>
</table>

---

**Table III** PCTS:porphyrin excretion after prolonged remission

<table>
<thead>
<tr>
<th>Patient</th>
<th>Urine (nmol/24h)</th>
<th>Faeces (nmol/g dry wt)</th>
<th>Isocopro Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Copro</td>
<td>Uro</td>
<td>Copro: Uro</td>
</tr>
<tr>
<td>1</td>
<td>174</td>
<td>54</td>
<td>26</td>
</tr>
<tr>
<td>2</td>
<td>60</td>
<td>75</td>
<td>47</td>
</tr>
<tr>
<td>3</td>
<td>122</td>
<td>42</td>
<td>87</td>
</tr>
<tr>
<td>4a</td>
<td>101</td>
<td>542</td>
<td>60</td>
</tr>
<tr>
<td>5a</td>
<td>131</td>
<td>391</td>
<td>8</td>
</tr>
<tr>
<td>b</td>
<td>99</td>
<td>26</td>
<td>6</td>
</tr>
<tr>
<td>b</td>
<td>99</td>
<td>26</td>
<td>6</td>
</tr>
</tbody>
</table>

---

1 Hydroxyisocoproporphyrin always less than 'isocoproporphyrin';
2 Calculated assuming 20 g dry weight of faeces per day

---

Fig 2 Screening test for 'isocoproporphyrin'. Thin-layer chromatography of porphyrin esters from faeces of patients with PCTS (1) and VP (2, 3) and a normal subject (4) photographed under ultraviolet light.
Differentiation of porphryia cutanea tarda symptomatica from other types of porphryia

phyrin excretion (for 27 patients, \( r = 0.45, p < 0.05 \)). When remission is prolonged and porphryin excretion has returned almost to normal, urinary uroporphyrin excretion and the 'isocoproporphyrin' coproporphyrin ratio are more likely to be abnormal than the other measurements of porphryin excretion shown in table III.

Discussion

When VP presents with skin lesions unaccompanied by porphobilinogenurcia it can usually be differentiated from PCTS by measurement of urinary and faecal porphryin fractions using solvent partition techniques (Eales et al., 1963) (table I). Thus in VP the main abnormality is a marked increase in the excretion of porphyrins in the faeces, the concentration of porphyrin in the protoporphyrin fraction usually being about twice that in the coproporphyrin fraction. Urinary porphryin excretion may occasionally be normal, but in most patients there is some increase in coproporphyrin excretion. In PCTS, on the other hand, the characteristic abnormality is a great increase in the excretion of uroporphyrin in the urine, the rate of excretion always exceeding that of coproporphyrin. The faecal porphryin fractions are usually no more than moderately increased, with an increase in the coproporphyrin fraction as the most consistent abnormality (Eales et al., 1966). In a few patients difficulties in diagnosis arise because the concentration of uroporphyrin in the urine in VP may occasionally be greater than that of coproporphyrin, due to in vitro condensation of porphobilinogen, and because in a few patients faecal porphryin excretion may be as great in PCTS as in VP (Eales et al., 1966) (table I). In such patients it is convenient if a diagnosis can be made without collection of further samples of urine and faeces from the patient and other family members.

In recent years a number of methods for distinguishing between VP and PCTS that depend on measurement of individual porphyrins rather than porphryin fractions have been described. Rimington et al. (1968) reported that patients with VP excrete increased amounts of porphryin-peptide conjugates ('X porphryin'), mainly in their faeces, and suggested that determination of 'X porphryin' may be of diagnostic value. It is now clear that measurement of the 'X porphryin' fraction of faeces is no more effective than estimation of the ether-soluble porphryin fractions as a means of distinguishing VP from PCTS (Eales et al., 1971; Moore et al., 1972; Elder et al., 1974). Although the composition of this fraction is different in the two conditions (Elder et al., 1974), methods of analysis are too laborious for routine use. Other methods involve quantitative assessment of porphryin excretion patterns. Thus, Doss et al. (1971) have used thin-layer chromatography with fluorescence scanning to separate and measure urine porphyrins and have defined characteristic patterns for each of the hepatic porphyrias. Grosser and Eales (1973) used a similar thin-layer chromatographic method to examine the faecal porphryin patterns of PCTS and VP but concluded that separation of the two conditions was no better than with solvent partition techniques. Their thin-layer chromatography system did not separate 'isocoproporphyrin' from coproporphyrin and penta-carboxylate porphyrin.

Figure 3 shows that measurement of the 'isocoproporphyrin':coproporphyrin ratio in faeces is a reliable method of separating PCTS and VP. Although in the present series it was no more effective in this respect than the combination of measurements in table I, the technique was useful as a confirmatory test in the few patients with PCTS with high faecal porphyrin levels and in the one patient with VP in whom there was more uroporphyrin than coproporphyrin in the urine. Furthermore, the results reported here suggest that in the

![Figure 3](image-url)
majority of patients with PCTS increased excretion of porphyrins of the isocoproporphyrin series is to a large extent responsible for the increase in the faecal coproporphyrin fraction that has been considered a characteristic feature of the condition (Eales et al, 1966; Taddei and Watson, 1968). The results in table III show that measurement of the ‘isocoproporphyrin’:coproporphyrin ratio is likely to be useful for assessing the significance of minor abnormalities of porphyrin excretion, particularly when these are found in the relatives of patients with PCTS and in patients with liver disease, both situations in which latent PCTS may be commoner than previously suspected (Doss et al, 1971; Dehlin et al, 1973).

It is not clear whether the absence of ‘isocoproporphyrin’ from the faeces of the majority of normal subjects and patients with types of porphyria other than PCTS reflects a true failure to form or excrete these porphyrins or whether it is explained by a lack of sensitivity in the method of detection, the lower limit of detectability coinciding with the upper end of the normal range for the ratio. Unfortunately, when ‘isocoproporphyrin’ was detected in normal faeces, the ratio could not be measured because, due to the large amount of non-porphyrin material relative to porphyrin in the extracts, it was impossible to apply sufficient porphyrin to the plates to obtain measurable amounts of ‘isocoproporphyrin’. Thus it is not possible to say whether the ‘isocoproporphyrin’:coproporphyrin ratio, as well as the concentration of ‘isocoproporphyrin’ in the faeces, was higher in the three patients with VP than in the four non-porphyric subjects.

The excretion of porphyrins of the isocopro-
aporphyrin series by some patients with VP, by a patient with atypical congenital erythropoietic porphyria (Rimington and With, 1973; Eriksen and Eriksen, 1974), and by some normal subjects, emphasizes that these porphyrins, like the other porphyrins excreted in excess in PCTS, are not metabolites unique to this condition. It is probable that in both liver and erythropoietic cells pentacarboxylate porphyrinogen III can be metabolized either to coproporphyrinogen III or to dehydroisocoproporphyrinogen, the precursor of porphyrins of the isocoproporphyrin series (Elder, 1972). In normal circumstances, coproporphyrinogen III is the major product. In PCTS, pentacarboxylate porphyrinogen accumulates and the proportion converted to dehydroisocoproporphyrinogen appears to be greatly increased.

Eriksen and Eriksen (1974) have suggested that the conversion of pentacarboxylate porphyrinogen III to coproporphyrinogen III is impaired in the bone marrow of their patient with atypical congenital erythropoietic porphyria and that as a result pentacarboxylate porphyrinogen is metabolized to protoporphyrin IX via dehydroisocoproporphyrinogen, thus bypassing coproporphyrinogen III. Although it is possible that the same alternative route is important as a pathway for haem synthesis in the liver in PCTS, it is more likely that the same biochemical defect which leads to accumulation of pentacarboxylate porphyrinogen in PCTS prevents metabolism of dehydroisocoproporphyrinogen, since utilization of each compound for haem synthesis involves decarboxylation of the acetate β-substituent that is common to both.

I thank Professor C. H. Gray of the Department of Chemical Pathology, King’s College Hospital Medical School, where much of this work was done, for advice and encouragement; Professor S. M. Joubert, of the Department of Chemical Pathology, University of Natal, Durban, South Africa, and Professor I. A. Magnus, of the Institute of Dermatology, London E9, for sending samples for analysis; and the Medical Research Council for a Clinical Research Fellowship.

References


Differentiation of porphyria cutanea tarda symptomatica from other types of porphyria
